Papers/PMID:38563131
Efficacy and safety of topical rosuvastatin & melatonin vs. placebo in patients with mild to moderate plaque psoriasis: A preliminary randomized double-blinded clinical trial.
Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)2024The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
melatonin — no detected effect on psoriasis Area and Severity Index (PASI) score
LikelyGrade B, Likely. Human evidence with one recorded weakness, or capped at B by its design or by unread numbers.FindingNull result“Although the PASI score in the melatonin and rosuvastatin groups compared with placebo decreased, the changes were not significant.”
Quoted verbatim from Efficacy and safety of topical rosuvastatin & melatonin vs. placebo in patients with mild to moderate plaque psoriasis: A preliminary randomized double-blinded clinical trial.. - Study
- RCT
- Dose
- melatonin cream 5.0% (w/w) applied twice a day
- Population
- adults with mild-to-moderate plaque psoriasis; melatonin cream 5% w/w vs placebo cream, applied twice daily for 8 weeks
Efficacy and safety of topical rosuvastatin & melatonin vs. placebo in patients with mild to moderate plaque psoriasis: A preliminary randomized double-blinded clinical trial.2024PMID:38563131Permalink